Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, and its incidence is increasing. PDAC often shows resistance to several therapeutic modalities and a higher recurrence rate after surgical treatment in the early localized stage. Combination chemotherapy in advanced pancreatic cancer has minimal impact on overall survival. RNA interference (RNAi) is a promising tool for regulating target genes to achieve sequence-specific gene silencing. Here, we summarize RNAi-based therapeutics using nanomedicine-based delivery systems that are currently being tested in clinical trials and are being developed for the treatment of PDAC. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) genome editing has been widely used for the development of cancer models as a genetic screening tool for the identification and validation of therapeutic targets, as well as for potential cancer therapeutics. This review discusses current advances in CRISPR/Cas9 technology and its application to PDAC research. Continued progress in understanding the PDAC tumor microenvironment and nanomedicine-based gene therapy will improve the clinical outcomes of patients with PDAC.
Although there have been world-wide huge efforts in the field of cancer research to overcome cancer, the therapeutic influence is not satisfactory level yet, because of the diversity and complexity of cancers. The lack of preclinical models for translational research reliably predicting clinical activity of novel therapeutics is another obstacle in cancer research. Xenotransplantation of human cancer cell line into immunodeficient mice is very useful for studying human cancer therapy. However, these animal models have been limited to reflect a practical consideration of clinic and genetic diversity of patients. The creation of patient-derived xenografts (PDX) that carry partial or complete human physiological systems has been certainly accepted as a helpful tool to overcome these obstacles. We have established total 339 cases in total (lung 79 cases, liver 109 cases, stomach 106 cases and colon 45 cases) up to date, and they were analyzed for the gene mutations by “Onco map” method, in order to compare to the original patient-tumor. As a result of cytogenetically homology comparison and finger printing, PDX tumors represent the same characteristics of the original PD tumors. These PDX models have been practically used for the translational research for personalized cancer therapeutics. This study represents new technologies for translational research platform of personalized cancer therapeutics. Additionally, these translational research platform promise the new access in many other studies such as a drug efficacy test, target discovery and co-clinical study. Citation Format: Hyeji Park, Eun Jin Ju, Jinhyang Choi, Seok Soon Park, Jaesook Park, Jae Hee Lee, Seol Hwa Shin, Seong-Yun Jeong, Si Yeol Song, Eun Kyung Choi. Establishment and application of patient-derived xenograft models for translational research of personalized cancer therapeutics. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-33. doi:10.1158/1538-7445.AM2014-LB-33
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.